Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 17965891)

  • 1. Cost-effectiveness analysis of aprepitant in the prevention of chemotherapy-induced nausea and vomiting in Belgium.
    Annemans L; Strens D; Lox E; Petit C; Malonne H
    Support Care Cancer; 2008 Aug; 16(8):905-15. PubMed ID: 17965891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis.
    Piechotta V; Adams A; Haque M; Scheckel B; Kreuzberger N; Monsef I; Jordan K; Kuhr K; Skoetz N
    Cochrane Database Syst Rev; 2021 Nov; 11(11):CD012775. PubMed ID: 34784425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic analysis of aprepitant-containing regimen to prevent chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy in Hong Kong.
    Chan SL; Jen J; Burke T; Pellissier J
    Asia Pac J Clin Oncol; 2014 Mar; 10(1):80-91. PubMed ID: 24571059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy.
    Yeo W; Mo FK; Suen JJ; Ho WM; Chan SL; Lau W; Koh J; Yeung WK; Kwan WH; Lee KK; Mok TS; Poon AN; Lam KC; Hui EK; Zee B
    Breast Cancer Res Treat; 2009 Feb; 113(3):529-35. PubMed ID: 18327706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with highly emetogenic chemotherapy.
    Moore S; Tumeh J; Wojtanowski S; Flowers C
    Value Health; 2007; 10(1):23-31. PubMed ID: 17261113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health outcomes and cost-effectiveness of aprepitant in outpatients receiving antiemetic prophylaxis for highly emetogenic chemotherapy in Germany.
    Lordick F; Ehlken B; Ihbe-Heffinger A; Berger K; Krobot KJ; Pellissier J; Davies G; Deuson R
    Eur J Cancer; 2007 Jan; 43(2):299-307. PubMed ID: 17134890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America.
    Poli-Bigelli S; Rodrigues-Pereira J; Carides AD; Julie Ma G; Eldridge K; Hipple A; Evans JK; Horgan KJ; Lawson F;
    Cancer; 2003 Jun; 97(12):3090-8. PubMed ID: 12784346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of clinical outcomes and efficacy of palonosetron and granisetron in combination with dexamethasone in Egyptian patients receiving highly emetogenic chemotherapy.
    A Mahrous M; A El-Azab G; A Tawfik H
    Cancer Chemother Pharmacol; 2021 Jul; 88(1):121-129. PubMed ID: 33835230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study.
    Rapoport BL; Jordan K; Boice JA; Taylor A; Brown C; Hardwick JS; Carides A; Webb T; Schmoll HJ
    Support Care Cancer; 2010 Apr; 18(4):423-31. PubMed ID: 19568773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group.
    Hesketh PJ; Grunberg SM; Gralla RJ; Warr DG; Roila F; de Wit R; Chawla SP; Carides AD; Ianus J; Elmer ME; Evans JK; Beck K; Reines S; Horgan KJ;
    J Clin Oncol; 2003 Nov; 21(22):4112-9. PubMed ID: 14559886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aprepitant: a review of its use in the prevention of nausea and vomiting.
    Curran MP; Robinson DM
    Drugs; 2009; 69(13):1853-78. PubMed ID: 19719336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-utility analysis of aprepitant for patients who truly need it in Japan.
    Tsukiyama I; Ando M; Tsukiyama S; Takeuchi M; Ejiri M; Kurose Y; Saito H; Arakawa I; Inoue T; Yamaguchi E; Kubo A
    Support Care Cancer; 2019 Oct; 27(10):3749-3758. PubMed ID: 30710243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential time course of action of 5-HT3 and NK1 receptor antagonists when used with highly and moderately emetogenic chemotherapy (HEC and MEC).
    Hesketh PJ; Warr DG; Street JC; Carides AD
    Support Care Cancer; 2011 Sep; 19(9):1297-302. PubMed ID: 20623144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resource utilization and costs associated with chemotherapy-induced nausea and vomiting (CINV) following highly or moderately emetogenic chemotherapy administered in the US outpatient hospital setting.
    Burke TA; Wisniewski T; Ernst FR
    Support Care Cancer; 2011 Jan; 19(1):131-40. PubMed ID: 20101417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of a fixed combination of netupitant and palonosetron (NEPA) relative to aprepitant plus granisetron (APR + GRAN) for prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a trial-based analysis.
    Botteman M; Nickel K; Corman S; Turini M; Binder G
    Support Care Cancer; 2020 Feb; 28(2):857-866. PubMed ID: 31161436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of aprepitant for prevention of chemotherapy-induced nausea and vomiting with moderately and highly emetogenic chemotherapy.
    Molassiotis A; Nguyen AM; Rittenberg CN; Makalinao A; Carides A
    Future Oncol; 2013 Oct; 9(10):1443-50. PubMed ID: 23987791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized, double-blind, placebo-controlled study of aprepitant versus two dosages of olanzapine with ondansetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving high-emetogenic chemotherapy.
    Ithimakin S; Theeratrakul P; Laocharoenkiat A; Nimmannit A; Akewanlop C; Soparattanapaisarn N; Techawattanawanna S; Korphaisarn K; Danchaivijitr P
    Support Care Cancer; 2020 Nov; 28(11):5335-5342. PubMed ID: 32128615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Best Practice Approach to Successful Conversion of Fosaprepitant to Aprepitant IV in a Large Multisite Community Oncology Infusion Center: A Retrospective Analysis.
    Burns D; Kula J; Marshall S; Ashworth E; Ornelas M
    Adv Ther; 2020 Jul; 37(7):3265-3277. PubMed ID: 32447650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
    de Wit R; Herrstedt J; Rapoport B; Carides AD; Guoguang-Ma J; Elmer M; Schmidt C; Evans JK; Horgan KJ
    Eur J Cancer; 2004 Feb; 40(3):403-10. PubMed ID: 14746859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic and preventive antiemetic effect of aprepitant in Japanese patients with thoracic malignancies who truly need it.
    Ito S; Tsukiyama I; Ando M; Katakami M; Hamanaka R; Kosaka K; Matsubara A; Nishimura M; Tanaka H; Asai N; Yokoe N; Takahashi A; Baba K; Matsuura K; Yamaguchi E; Kubo A
    Support Care Cancer; 2015 Apr; 23(4):905-12. PubMed ID: 25223352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.